MINE-R regimen
|
WikiDoc Resources for MINE-R regimen |
|
Articles |
|---|
|
Most recent articles on MINE-R regimen Most cited articles on MINE-R regimen |
|
Media |
|
Powerpoint slides on MINE-R regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on MINE-R regimen at Clinical Trials.gov Trial results on MINE-R regimen Clinical Trials on MINE-R regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on MINE-R regimen NICE Guidance on MINE-R regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on MINE-R regimen Discussion groups on MINE-R regimen Patient Handouts on MINE-R regimen Directions to Hospitals Treating MINE-R regimen Risk calculators and risk factors for MINE-R regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for MINE-R regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Mesna-Ifosfamide-Novantrone-Etoposide-Rituximab Regimen; MINE-R Regimen
Overview
MINE-R regimen refers to a regimen consisting of mesna, ifosfamide, mitoxantrone, etoposide, and rituximab used to treat relapsed or refractory Hodgkin's lymphoma and non-Hodgkin's lymphoma.[1]
Regimen
MMesna
IIfosfamide
NMitoxantrone (Novantrone)
EEtoposide
RRituximab
Indications
Hodgkin's lymphoma and non-Hodgkin's lymphoma[1]
References
- ↑ 1.0 1.1 Rehwald U, Schulz H, Reiser M, Sieber M, Staak JO, Morschhauser F; et al. (2003). "Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group". Blood. 101 (2): 420–4. doi:10.1182/blood.V101.2.420. PMID 12509381.